Search results
Results from the WOW.Com Content Network
The 340B Drug Pricing Program is a US federal government program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. The intent of the program is to allow covered entities to "stretch scarce federal resources as far as possible ...
One of the following programs is the 340B pricing program that allows hospitals and pharmacists to buy drugs at 30–50% off the retail prices. [71] Per HRSA's 340B Drug Pricing Program , drug manufacturers are required to give certain organizations discounted drugs given these organizations fit the eligibility criteria for discounts. [ 72 ]
Ten drugs are slated to have their prices slashed for Medicare recipients, but the drug industry is objecting to the new law. Medicare can now negotiate prices on these drugs to help seniors save ...
Drug companies have typically supported capping the price older Americans pay for drugs because they don't eat the cost — insurers or Americans who pay premiums do. “It makes it easier for ...
Program flexibility that supports the Health Plan Sponsor's current prescription drug plan structure Extensive educational materials and support To qualify for the subsidy, a Health Plan Sponsor must show that its coverage is "actuarially equivalent" to, or at least as generous as, the defined standard Medicare Part D coverage.
The 340B drug pricing program, originally intended to help low-income and uninsured patients, has been exploited by special interests for profit, resulting in higher drug prices, taxes, and ...
Lists of all drugs that have received orphan status in the United States and Europe are available from the U.S. Food and Drug Administration and the European Commission, respectively: FDA List of Orphan Designations and Approvals [dead link ] European Commission Register of designated Orphan Medicinal Products
According to Thomson Reuters in their 2012 publication "The Economic Power of Orphan Drugs", there has been increased investing in orphan drug research and development partly since the U.S. Congress enacted the Orphan Drug Act, giving an extra monopoly for drugs for "orphan diseases" that affected fewer than 200,000 people in the country. [13]